Ligand Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Ligand Pharmaceuticals Inc. filed its 2023 10-K report, detailing financial performance and business operations.</b>

AI Summary

LIGAND PHARMACEUTICALS INC (LGNZZ) filed a Annual Report (10-K) with the SEC on February 29, 2024. Ligand Pharmaceuticals Inc. reported its 2023 fiscal year results on February 29, 2024. The company's primary business is in Pharmaceutical Preparations, SIC code 2834. Key financial data for the fiscal year ending December 31, 2023, is detailed in the filing. The filing includes information on royalty and contract revenues for 2023, 2022, and 2021. Specific details on Captisol material sales are also provided for the same periods.

Why It Matters

For investors and stakeholders tracking LIGAND PHARMACEUTICALS INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Ligand's financial health and operational status for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. The detailed breakdown of revenues, including royalties and Captisol sales, offers insights into the company's core business drivers and their trends over the past three years.

Risk Assessment

Risk Level: medium — LIGAND PHARMACEUTICALS INC shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, market competition, and patent expirations, posing inherent risks to revenue streams and profitability.

Analyst Insight

Investors should review the detailed revenue segments and risk factors in the 10-K to understand Ligand's business model and potential growth opportunities.

Revenue Breakdown

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-02-29 — Filing Date (Date of submission)
• 108 — Public Document Count (Number of documents in the filing)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

• LIGAND PHARMACEUTICALS INC (company) — Filer name
• 0000886163 (company) — Central Index Key
• 2834 (industry) — Standard Industrial Classification
• DE (jurisdiction) — State of Incorporation
• SAN DIEGO (location) — Business Address City
• CA (location) — Business Address State
• 92121 (postal_code) — Business Address Zip
• 20231231 (date) — Fiscal Year End

FAQ

Risk Factors

• Regulatory Environment [medium — regulatory]: The pharmaceutical industry is subject to extensive regulation by government agencies, impacting product development, marketing, and sales.
• Market Competition [medium — market]: Ligand operates in a competitive market with other pharmaceutical companies, which can affect market share and pricing.
• Dependence on Key Products/Partnerships [medium — financial]: The company's financial performance may be significantly influenced by the success and sales of its key products and the performance of its partners.

Key Financial Figures

• $750.0 million — NS Abbreviation Definition 2023 Notes $750.0 million aggregate principal amount of convertib
• $1 billion — ss model in 2007, we have deployed over $1 billion of capital to build our diverse portfol
• $15 million — ment with Primrose, whereby we invested $15 million in exchange for a portion of the econom
• $30 million — ber 2023, we announced an investment of $30 million to acquire a 13% portion of the royalti
• $20 million — r later. In November 2023, we closed a $20 million acquisition of Tolerance Therapeutics,
• $2.9 billion — ELD is marketed by Sanofi following its $2.9 billion acquisition of Provention Bio in 2023.
• $12.2 million — r 2023, the bankruptcy court approved a $12.2 million bid from Ligand to purchase certain ass

Filing Documents

• lgnd-20231231.htm (10-K) — 2495KB
• exhibit1012_amendmenttolig.htm (EX-10.12) — 6KB
• exhibit1044_palvella-first.htm (EX-10.44) — 18KB
• ligand-ex1045xpalvellaxame.htm (EX-10.45) — 94KB
• lgnd_123123xexhibit211.htm (EX-21.1) — 12KB
• lgnd_123123xexhibit231.htm (EX-23.1) — 6KB
• lgnd_123123xexhibit311.htm (EX-31.1) — 15KB
• lgnd_123123xexhibit312.htm (EX-31.2) — 15KB
• lgnd_123123xexhibit321.htm (EX-32.1) — 13KB
• exhibit97_ligand-clawbackp.htm (EX-97) — 27KB
• image_10.jpg (GRAPHIC) — 0KB
• image_11.jpg (GRAPHIC) — 0KB
• image_5.jpg (GRAPHIC) — 6KB
• lgnd-20231231_g1.jpg (GRAPHIC) — 39KB
• lgnd-20231231_g2.jpg (GRAPHIC) — 135KB
• lgnd-20231231_g3.jpg (GRAPHIC) — 99KB
• lgnd-20231231_g4.jpg (GRAPHIC) — 403KB
• 0000886163-24-000009.txt (&nbsp;) — 15027KB
• lgnd-20231231.xsd (EX-101.SCH) — 88KB
• lgnd-20231231_cal.xml (EX-101.CAL) — 155KB
• lgnd-20231231_def.xml (EX-101.DEF) — 521KB
• lgnd-20231231_lab.xml (EX-101.LAB) — 1230KB
• lgnd-20231231_pre.xml (EX-101.PRE) — 786KB
• lgnd-20231231_htm.xml (XML) — 2041KB

Risk Factors

Item 1A. Risk Factors 21

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 42

Cybersecurity

Item 1C. Cybersecurity 43

Properties

Item 2. Properties 45

Legal Proceedings

Item 3. Legal Proceedings 45

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 45 Part II

Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 45

[Reserved]

Item 6. [Reserved] 47

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 47

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 56

Consolidated Financial Statements and Supplementary Data

Item 8. Consolidated Financial Statements and Supplementary Data 56

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 95

Controls and Procedures

Item 9A. Controls and Procedures 95

Other Information

Item 9B. Other Information 95

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 95 Part III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 100

Executive Compensation

Item 11. Executive Compensation 100

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 100

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 100

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 100 Part IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 101

Form 10-K - Summary

Item 16. Form 10-K - Summary 101

Signatures

Signatures 105 GLOSSARY OF TERMS AND ABBREVIATIONS Abbreviation Definition 2023 Notes $750.0 million aggregate principal amount of convertible senior unsecured notes due 2023 Aldeyra Aldeyra Therapeutics, Inc. Amgen Amgen, Inc. ASC Accounting Standards Codification ASU Accounting Standards Update Aziyo Aziyo Med, LLC Baxter Baxter International, Inc. BeiGene BeiGene, Ltd. BendaRx BendaRx Corp. BLA Biologics license application CASI CASI Pharmaceuticals, Inc. cGMP Current Good Manufacturing Practice Company Ligand Pharmaceuticals Incorporated, including subsidiaries Convertible Note Senior Convertible Promissory Note COPD Chronic obstructive pulmonary disease Cormatrix Cormatrix Cardiovascular, Inc. Corvus Corvus Pharmaceuticals, Inc. Credit Agreement Credit Agreement, dated as of October 12, 2023, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein), and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer. CVR Contingent value right CyDex CyDex Pharmaceuticals, Inc. Daiichi Sankyo Daiichi Sankyo Company, Ltd. Dianomi Dianomi Therapeutics, Inc. DMF Drug Master File ESG Environmental, Social and Governance ECM Extracellular matrix Eisai Eisai Inc. Elutia Elutia Inc. EPA Environmental Protection Agency ESPP Employee Stock Purchase Plan, as amended and restated EU European Union Exelixis Exelixis, Inc. FASB Financial Accounting Standards Board FDA U.S. Food and Drug Administration FSGS Focal segmental glomerulosclerosis FY 2023 The Company's fiscal year ended December 31, 2023 FY 2022 The Company's fiscal year ended December 31, 2022 FY 2021 The Company's fiscal year ended December 31, 2021 GAAP Generally accepted accounting principles in the United States GCSF Granulocyte-colony stimulating factor Gilead Gilead Sciences, Inc. HBV Hepatitis B Virus Hikma Hikma Pharmaceuticals PLC Hovione Hovione FarmCiencia, S.A. IM

Business

Item 1. Business Overview We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world's leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. Our revenue consists of three primary elements: royalties from commercialized products, sales of our Captisol material to partners, and contract revenue from license fees and milestones payments. Strategy and Execution We are a biopharmaceutical royalty aggregator, focused on investing in differentiated late-stage assets and operating royalty-generating, infrastructure-light platform technologies. Since our transition to this business model in 2007, we have deployed over $1 billion of capital to build our diverse portfolio. Following the spin-offs of our OmniAb

View Full Filing

View this 10-K filing on SEC EDGAR